EEHV1A glycoprotein B subunit vaccine elicits humoral and cell-mediated immune responses in mice

• Published in: Vaccine Vol. 40; no. 35; pp. 5131 - 5140
• Main Authors: Spencer Clinton, Jennifer L., Hoornweg, Tabitha E., Tan, Jie, Peng, Rongsheng, Schaftenaar, Willem, Rutten, Victor P.M.G., de Haan, Cornelis A.M., Ling, Paul D.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 19.08.2022; Elsevier Limited
• Subjects: adjuvants; Allergy and Immunology; Animals; Antibodies; CD4 antigen; CD8 antigen; Cell-mediated immunity; death; Elephant endotheliotropic herpesvirus; Elephantid betaherpesvirus 1; Elephants; Endangered species; Europe; Glycoprotein B; Glycoproteins; Hemorrhage; Hemorrhagic disease; Herpesviridae; Herpesviridae Infections - prevention & control; Herpesviridae Infections - veterinary; Herpesvirus; Humoral immunity; Immune response; Immune response (cell-mediated); Immune response (humoral); Immunity; Immunity, Cellular; Infections; juveniles; Laboratories; Lymphocytes; Lymphocytes T; Mice; North America; Ostomy; Plasmids; protein subunits; Proteins; Robustness; Saponins; subunit vaccines; Vaccination; Vaccine; Vaccines; Vaccines, Subunit; North America; Europe; Vaccine; Herpesvirus; Elephant endotheliotropic herpesvirus
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2022.07.016

Asian elephants are an endangered species facing many threats, including severe hemorrhagic disease (HD) caused by the elephant endotheliotropic herpesvirus (EEHV). EEHV-HD is the leading cause of death in captive juvenile Asian elephants in North America and Europe, and also affects elephants in their natural range countries. Significant challenges exist for successful treatment of EEHV-HD, which include timely recognition of disease onset and limited availability of highly effective treatment options. To address this problem, our goal is to prevent lethal disease in young elephants by developing a vaccine that elicits robust and durable humoral and cell-mediated immunity against EEHV. EEHV glycoprotein B (gB) is a major target for cellular and humoral immunity in elephants previously exposed to EEHV. Therefore, we generated a vaccine containing recombinant EEHV1A gB together with a liposome formulated TLR-4 and saponin combination adjuvant (SLA-LSQ). CD-1 mice that received one or two vaccinations with the vaccine elicited significant anti-gB antibody and polyfunctional CD4+ and CD8+ T cell responses, while no adverse effects of vaccination were observed. Overall, our findings demonstrate that an adjuvanted gB protein subunit vaccine stimulates robust humoral and cell-mediated immune responses and supports its potential use in elephants.